Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

UCB SA Add to portfolio

N100:UCB, Nov 22, 07:07 UTC

Latest N100:UCB News

Filter your feed

Apply Filter

Friday, November 08


News

UCB (OTCMKTS:UCBJF) Stock Price Up 2.1%

UCB

Shares of UCB SA (OTCMKTS:UCBJF) rose 2.1% on Wednesday . The company traded as high as $75.42 and last traded at $75.42, approximately 449 shares were traded during mid-day trading. ValuEngine raised UCB from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. The business has a fifty day moving average price of $72.72 and a two-hundred day moving average price of $77.44.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, November 07


News

Global Epilepsy Drugs Market 2019 – Abbott Laboratories , GlaxoSmithKline Plc , UCB , Cephalon , Johnson & Johnson , Pfizer – Globe News Reports

UCB JNJ +2 more UCB JNJ GSK GSK

Global Epilepsy Drugs Market 2019 – Abbott Laboratories , GlaxoSmithKline Plc , UCB , Cephalon , Johnson & Johnson , Pfizer. The advancement rate is evaluated dependent on insightful examination that gives the authentic information on the worldwide Epilepsy Drugs market. The report is all around made by considering its essential information in the overall Global Epilepsy Drugs market 2019, the essential components in charge of the interest for its items and administrations. The Global Epilepsy Drugs market 2019 report displays a point by point division of the overall market subject to development, item type, application, and distinctive methods and systems.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, November 06


News

Should You Be Careful About Investing In Stock?:Ucb, The Belgium, (Euronext BE:UCB.BB) – News Soloution

UCB

03-Months changes: $08 with the percentage of : 7.44%. 50-Days Moving Average (MA) recorded as: 67.128, (MA-50 is used by traders to gauge mid-term trends). A stochastic oscillator is a momentum indicator comparing a particular closing price of a security to a range of its prices over a certain period of time. The sensitivity of the oscillator to market movements is reducible by adjusting that time period or by taking a moving average of the result.

Read Full Details

Topics:
  • Business
  • Financial
News

Take a snapshot of Stock: UCB SA (EURONEXT:UCB)

UCB BNP

UCB SA stock has performed -0.22% and changed €-0.16 while share value reached at €73.34 in last trading session. At present, the stock 52 week high price sited at 80.06 and 52 week low situated at 62.26. Analysts estimated that stock to reach value at €74.54 price in one-year period. Volatility or average true range percent (ATRP 14) is the ATR expressed as a percentage of closing price.

Read Full Details

Topics:
  • Business
  • Financial
News

Global Novel Drug Delivery Systems Market Top Players 2019 - 2025 : Amgen, Teva, Union Chimique Belge (UCB), Roche - Maxi Wire

UCB

The research covers the current market size of the market and its growth rates based on 5-year records with company outline of key players/manufacturers:Amgen, Teva, Union Chimique Belge (UCB), Roche, Celgene, Sanofi, Merck, Johnson & Johnson, Takeda, Gilead Sciences, Pfizer, Dr Reddy, Samyang Biopharmaceuticals, TOLMAR, Astellas, AMAG Pharmaceuticals, AstraZeneca, AbbVie, Bausch?Lomb, TWi Pharmaceuticals, Novartis, Aspen, Shire, Breckenridge Pharmaceuticals, Galen. The analysts have profiled leading players of the global Novel Drug Delivery Systems market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects. Analysts also reflected every factor that could be used to distinguish drivers, limitations, opportunities and threats of the Global Novel Drug Delivery Systems Market. Some of these influences include annual revenue, key segments, production capacity and new products. This is coupled with understanding business practices of the market, sympathetic government’s presence in the industry, classifying leverage of Global Novel Drug Delivery Systems market globally, reviewing commercial terms and conditions and analyzing market subjects and trends.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, November 02


News

UCB S A/ADR (OTCMKTS:UCBJY) Upgraded to Neutral by JPMorgan Chase & Co. – Slater Sentinel

UCB

UCB S A/ADR (OTCMKTS:UCBJY) Upgraded to Neutral by JPMorgan Chase & Co. Saturday, November 2nd, 2019. JPMorgan Chase & Co. upgraded shares of UCB S A/ADR (OTCMKTS:UCBJY) from an underweight rating to a neutral rating in a research report released on Tuesday, The Fly reports. UCB S A/ADR has a fifty-two week low of $34.60 and a fifty-two week high of $44.65. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, October 27


News

ImmunoGen (NASDAQ:IMGN) versus UCB (NASDAQ:UCBJF) Financial Survey – Riverton Roll

UCB

ImmunoGen (NASDAQ:IMGN) and UCB (OTCMKTS:UCBJF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. This is a breakdown of current ratings and target prices for ImmunoGen and UCB, as reported by MarketBeat.com. Given ImmunoGen’s higher probable upside, equities research analysts plainly believe ImmunoGen is more favorable than UCB.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, October 20


News

UCB (OTCMKTS:UCBJF) Upgraded by Citigroup to Buy – Slater Sentinel

UCB

Citigroup upgraded shares of UCB (OTCMKTS:UCBJF) from a neutral rating to a buy rating in a research note released on Wednesday morning, The Fly reports. Separately, ValuEngine upgraded UCB from a sell rating to a hold rating in a research note on Wednesday, October 2nd. UCB has a 12-month low of $68.95 and a 12-month high of $88.67. The stock’s 50-day moving average price is $72.05 and its 200 day moving average price is $78.65.

Read Full Details

Topics:
  • Business
  • Financial

Friday, October 18


News

Global Epilepsy Drugs Market 2019 – Abbott Laboratories , GlaxoSmithKline Plc , UCB , Cephalon , Johnson & Johnson , Pfizer – Market News Reports

UCB JNJ +2 more UCB JNJ GSK GSK

Do Inquiry For More Details : http://www.mrsresearchgroup.com/report/137530#inquiry-for-buying. Chapter 1: Introduction, Definition, Specifications, Classification and Scope the Epilepsy Drugs market 2019Chapter 2: Exclusive Summery like Industry chain structure, Manufacturer cost structure, suppliers, etcChapter 3: Displays Trends, Drivers and Challenges of the Epilepsy Drugs marketChapter 4: By the study of SWOT analysis it displays sales analysis, investment analysis, market analysis, etcChapter 5: It evaluate the market by segments, by countries and by manufacturers with revenue, share and sales by key countries in these various regions.Chapter 6: Evaluate the leading manufacturers of the Global Epilepsy Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company ProfileChapter 7: Epilepsy Drugs Research Findings and Conclusion, Appendix, system and information source. The report provides data analyzed graphically for a better explanation. Our experts have crafted the full study of Epilepsy Drugs market 2019 in a structured format for better interpretation.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
  • Science

Sunday, October 13


News

Global Epilepsy Drugs Market 2019 – Abbott Laboratories , GlaxoSmithKline Plc , UCB , Cephalon , Johnson & Johnson , Pfizer – Industry Press Release

UCB JNJ +2 more UCB JNJ GSK GSK

Global Epilepsy Drugs Market 2019 – Abbott Laboratories , GlaxoSmithKline Plc , UCB , Cephalon , Johnson & Johnson , Pfizer. The advancement rate is evaluated dependent on insightful examination that gives the authentic information on the worldwide Epilepsy Drugs market. The report is all around made by considering its essential information in the overall Global Epilepsy Drugs market 2019, the essential components in charge of the interest for its items and administrations. The Global Epilepsy Drugs market 2019 report displays a point by point division of the overall market subject to development, item type, application, and distinctive methods and systems.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
  • Science